These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 8678017)

  • 1. Drug-induced vanishing bile duct syndrome: response to ursodiol.
    O'Brien CB; Shields DS; Saul SH; Reddy KR
    Am J Gastroenterol; 1996 Jul; 91(7):1456-7. PubMed ID: 8678017
    [No Abstract]   [Full Text] [Related]  

  • 2. Ursodeoxycholic acid in the treatment of AIDS-associated cholangiopathy.
    Castiella A; Iribarren JA; López P; Arrizabalaga J; Rodríguez F; von Wichmann MA; Arenas JI
    Am J Med; 1997 Aug; 103(2):170-1. PubMed ID: 9274905
    [No Abstract]   [Full Text] [Related]  

  • 3. Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children.
    Lebensztejn DM
    Med Sci Monit; 2000; 6(3):632-6. PubMed ID: 11208384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bile duct disorders.
    Geubel AP; Sempoux C; Rahier J
    Clin Liver Dis; 2003 May; 7(2):295-309. PubMed ID: 12879985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favourable long term effect of ursodeoxycholic acid treatment on congenital vanishing bile duct syndromes.
    Karageorgos SA; Tzardi M; Stratakou S; Voumvouraki A; Notas G; Kouroumalis E
    Acta Gastroenterol Belg; 2018; 81(2):330-332. PubMed ID: 30024707
    [No Abstract]   [Full Text] [Related]  

  • 6. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
    Linares Rodríguez A
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
    [No Abstract]   [Full Text] [Related]  

  • 7. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
    Pusl T; Beuers U
    World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Autoimmune cholestasis syndrome. Ursodeoxycholic acid is the drug standard].
    Stiefelhagen P
    MMW Fortschr Med; 2007 May; 149(21):49. PubMed ID: 17668736
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cholestasis from ticlopidine: two clinical cases].
    Varvello L; Arnò C; Coggiola M; Ramassotto E; Pascale C
    Ann Ital Med Int; 2002; 17(4):252-5. PubMed ID: 12532564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute vanishing bile duct syndrome after ibuprofen therapy in a child.
    Taghian M; Tran TA; Bresson-Hadni S; Menget A; Felix S; Jacquemin E
    J Pediatr; 2004 Aug; 145(2):273-6. PubMed ID: 15289784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vanishing bile duct syndrome associated with azithromycin in a 62-year-old man.
    Juricic D; Hrstic I; Radic D; Skegro M; Coric M; Vucelic B; Francetic I
    Basic Clin Pharmacol Toxicol; 2010 Jan; 106(1):62-5. PubMed ID: 19906050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodiol in patients with parenteral nutrition-associated cholestasis.
    San Luis VA; Btaiche IF
    Ann Pharmacother; 2007 Nov; 41(11):1867-72. PubMed ID: 17911205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ursodeoxycholic acid therapy in children with cholestatic liver disease.
    Dinler G; Koçak N; Yüce A; Gürakan F; Ozen H
    Turk J Pediatr; 1999; 41(1):91-8. PubMed ID: 10770681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Successful therapy of persistent androgen-induced cholestasis with ursodeoxycholic acid].
    Mörk H; al-Taie O; Klinge O; Scheurlen M
    Z Gastroenterol; 1997 Dec; 35(12):1087-91. PubMed ID: 9487641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child.
    Srivastava M; Perez-Atayde A; Jonas MM
    Gastroenterology; 1998 Sep; 115(3):743-6. PubMed ID: 9721172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The biochemical and histopathological effects of ursodeoxycholic acid and metronidazole on total parenteral nutrition-associated hepatic dysfunction: an experimental study.
    Günsar C; Melek M; Karaca I; Sencan A; Mir E; Ortaç R; Canan O
    Hepatogastroenterology; 2002; 49(44):497-500. PubMed ID: 11995481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hepatobiliary disease in cystic fibrosis].
    Pérez-Aguilar F; Berenguer Lapuerta J
    Med Clin (Barc); 1998 Sep; 111(8):302-6. PubMed ID: 9810550
    [No Abstract]   [Full Text] [Related]  

  • 18. [Diseases of the intrahepatic bile duct: diagnosis and principles of treatment].
    Chazouillères O; Wendum D
    Gastroenterol Clin Biol; 2003 Mar; 27(3 Pt 1):307-18. PubMed ID: 12700519
    [No Abstract]   [Full Text] [Related]  

  • 19. Ursodeoxycholic acid for terbinafine-induced toxic hepatitis.
    Agca E; Akcay A; Simsek H
    Ann Pharmacother; 2004 Jun; 38(6):1088-9. PubMed ID: 15122001
    [No Abstract]   [Full Text] [Related]  

  • 20. Cholestasis secondary to Hodgkin's disease: report of 2 cases of vanishing bile duct syndrome.
    de Medeiros BC; Lacerda MA; Telles JE; da Silva JA; de Medeiros CR
    Haematologica; 1998 Nov; 83(11):1038-40. PubMed ID: 9864926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.